"Abbott delivered a clean beat in its most recent quarter. Net sales reached $11.164 billion, up 7.78% year-over-year, while adjusted diluted EPS came in at $1.15, extending a four-quarter streak of beating EPS estimates."
"The Exact Sciences deal positions Abbott as a leader in oncology diagnostics, a fast-growing market with significant underpenetration. CEO Robert Ford called it 'another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year.'"
"The stock fell roughly 4.7% on the day of the Q1 earnings beat, even as the broader market rose. That reaction signals real concern."
"Abbott has also declared its 409th consecutive quarterly dividend of $0.63 per share, its 54th consecutive year of dividend increases, a track record few companies match."
Abbott Laboratories has experienced stock price declines in 2026 despite a strong performance in its latest quarter, with net sales increasing by 7.78%. The acquisition of Exact Sciences has introduced integration costs and EPS dilution, raising concerns among investors. However, Abbott's leadership in oncology diagnostics positions it well for future growth. The company maintains a strong dividend history, declaring its 409th consecutive quarterly dividend. Full-year guidance suggests continued sales growth and stable earnings per share, indicating potential for recovery despite current market challenges.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]